Zevra Therapeutics (ZVRA) Research & Development (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Research & Development of $4.4 million for Q1 2026, up 67.63% on a QoQ basis from $2.6 million in Q4 2025, and up 34.81% year-over-year from $3.3 million in Q1 2025.
Zevra Therapeutics (ZVRA) Research & Development (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Research & Development history runs 13 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- Quarterly Research & Development rose 34.81% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (down 58.05% YoY) and the FY2025 annual result came in at $12.7 million, down 69.73% from the prior year.
- Research & Development was $4.4 million for Q1 2026 at Zevra Therapeutics, up from $2.6 million in the prior quarter.
- Across five years, Research & Development topped out at $19.8 million in Q4 2022 and bottomed at $2.6 million in Q4 2025.
- A 5-year average of $7.8 million and a median of $7.4 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 604.98% — and 2025, when it slumped 73.46%.
- Zevra Therapeutics' Research & Development stood at $19.8 million in 2022, then tumbled by 42.33% to $11.4 million in 2023, then retreated by 26.87% to $8.4 million in 2024, then plunged by 68.63% to $2.6 million in 2025, then jumped by 67.63% to $4.4 million in 2026.
- Business Quant data shows ZVRA's Research & Development at $4.4 million in Q1 2026, $2.6 million in Q4 2025, and $3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 4.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.39 Mn |
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | 3.43 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.26 Mn |
| Dec 31, 2024 | 8.35 Mn |
| Sep 30, 2024 | 10.95 Mn |
| Jun 30, 2024 | 10.52 Mn |
| Mar 31, 2024 | 12.28 Mn |
| Dec 31, 2023 | 11.42 Mn |
| Sep 30, 2023 | 12.30 Mn |
| Jun 30, 2023 | 7.43 Mn |
| Mar 31, 2023 | 8.66 Mn |
| Dec 31, 2022 | 19.80 Mn |
| Sep 30, 2022 | 5.39 Mn |
| Jun 30, 2022 | 4.80 Mn |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 2.81 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | 2.85 Mn |